MabThera licensed in CLL

MabThera (rituximab) is now indicated for use in combination with chemotherapy for the first-line treatment of chronic lymphocytic leukaemia (CLL).

The recommended dose for the new indication is 375mg/m2 by iv infusion on day one of first treatment cycle, prior to chemotherapy, then 500mg/m2 on day one of subsequent cycles for a total of six cycles.

View MabThera drug record

Further information: Roche

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases